ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Feb 05, 2020 19:40 JST
Source:
Jacobson Pharma Corporation Limited
Jacobson Pharma Launches First Influenza/RSV Home Diagnostic Kit in Hong Kong and Macau
HONG KONG, Feb 05, 2020 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in research, development, production, marketing and sale of generic drugs and branded healthcare products, announced the launch of its first home diagnostic product for influenza/RSV under the brand name of "Dr. Freeman Flu/RSV Combo" (the "Product") in Hong Kong and Macau since January 2020. The product is available in different over-the-counter channels including major healthcare chain stores and drug stores.
Jacobson launches Dr. Freeman Flu/RSV Combo as its first influenza/RSV home diagnostic kit in the markets of Hong Kong and Macau. It is designed for qualitative determination of specific types of Influenza A and B virus and respiratory syncytial virus ("RSV") with test results available in 8 minutes.
Dr. Freeman Flu/RSV Combo is a handy one-step home diagnostic test designed for qualitative determination of specific types of Influenza A and B virus and respiratory syncytial virus ("RSV") with test results available in 8 minutes. The Product marks the first among others of its home diagnostic portfolio to be launched under the branded healthcare business platform of the Group. The Group is contemplating a potential strategic spin-off of its branded healthcare business which comprises proprietary medicines, proprietary Chinese medicines and branded health and wellness products such as health supplements, personal care products and diagnostic kits.
In scientific terms, Dr. Freeman Flu/RSV Combo uses monoclonal antibodies specific to the corresponding antigens of influenza and RSV for determination of the specific types of influenza and RSV infected, apart from the indication of the presence of influenza.
Mr Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, commented, "We are very pleased for bringing in this useful home diagnostic product for influenza /RSV to the markets in Hong Kong and Macau. As a handy, speedy and specific self-diagnostic tool for the communicable disease, we believe the Product can highly benefit the public by helping influenza/RSV infected patients to seek prompt and effective medical treatment at the onset of the illnesses, especially during the peak flu seasons.
Bearing with the commitment to fulfilling unmet healthcare needs of consumers, we will continue to enhance our portfolio with high quality, innovative and well-trusted products in the expansion of our branded healthcare business as a strategic growth platform. Our ongoing efforts are set to strengthen our long-term strategic position and thereby enhancing the shareholders' values.".
About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading generic drug company in Hong Kong. The Group's proprietary brand portfolio, notably being Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex Scar Gel, Flying Eagle Wood Lok Medicated Oil, Tong Tai Chung Woodlok Oil, Doan's Ointment, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognised by the market. The Group aims at the continued strategic enrichment of both of its generic drug and branded healthcare portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website:
http://www.jacobsonpharma.com
For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email:
vicky.lee@sprg.com.hk
Stephanie Liu Tel: (852) 2864 4852 Email:
stephanie.liu@sprg.com.hk
Rachel Ko Tel: (852) 2864 4806 Email:
rachel.ko@sprg.com.hk
Fax: (852) 2527 1196
Source: Jacobson Pharma Corporation Limited
Sectors: Daily Finance, Daily News, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Honda Newly Launches "Discover Honda" Content Curation Media Platform
Dec 26, 2025 17:34 JST
Mazda Selected for A List in CDP Water Security for the First Time
Dec 26, 2025 17:19 JST
Fujitsu Develops Fujitsu Kozuchi Physical AI 1.0 for Seamless Integration of Physical and Agentic AI
Dec 26, 2025 14:04 JST
Establishment of DOCOMO Innovation Fund IV, a Corporate Venture Investment Fund
Dec 26, 2025 13:53 JST
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2025
Dec 26, 2025 11:00 JST
BCQ (01963.HK) to Pay RMB 585 Million Cash Dividend, Driving Share Price and Yield Upside
Dec 25, 2025 18:23 JST
Tohoku University and Fujitsu utilize Causal AI to discover superconductivity mechanism of promising new functional material
Dec 23, 2025 14:58 JST
Toward an Athlete- and Planet-Friendly Hakone Ekiden: All Vehicles Provided for the 2026 Race Will Be Electrified
Dec 23, 2025 03:18 JST
MHI Group to Accelerate Development of Digital Talent
Dec 23, 2025 02:57 JST
MHI and EXEO Group Build and Begin Commercial Use of Japan's First GPU Servers with Two-Phase DLC
Dec 23, 2025 02:20 JST
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City
Dec 19, 2025 03:24 JST
NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations
Dec 19, 2025 03:06 JST
Fujitsu to showcase mobility and physical AI tech at CES 2026
Dec 19, 2025 02:42 JST
Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology
Dec 19, 2025 02:06 JST
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming
Dec 18, 2025 22:00 JST
SAKENOVA: 28-Year-Old Master Brewer Pioneers AI-Driven Sake Revolution, Achieving 40% Cost Reduction While Winning International Gold Medals
Dec 15, 2025 23:00 JST
NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport
Dec 15, 2025 19:41 JST
NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz
Dec 15, 2025 19:04 JST
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
Dec 15, 2025 08:30 JST
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST
More Latest Release >>
Related Release
Jacobson Pharma Announces FY2025 Interim Results
November 22 2024 10:00 JST
Jacobson Pharma Announces FY2023 Interim Results
November 25 2022 21:21 JST
Jacobson Pharma Announces FY2022 Annual Results
June 29 2022 23:20 JST
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia
June 15 2022 19:56 JST
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60%
March 14 2022 19:58 JST
Jacobson Pharma Announces FY2022 Interim Results
November 26 2021 19:39 JST
Jacobson Pharma Announces FY2021 Annual Results
June 29 2021 23:19 JST
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
February 05 2021 16:28 JST
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
January 25 2021 17:20 JST
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
January 15 2021 23:25 JST
More Press release >>